# CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

> **NCT04156256** · EARLY_PHASE1 · UNKNOWN · sponsor: **iCell Gene Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Hematologic Malignancy
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm
- Chronic Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CD123-CD33 cCAR T cells

## Key facts

- **NCT ID:** NCT04156256
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-11-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156256, "CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04156256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*